DOCSLIB.ORG

RELATIVE BIOLOGICAL EFFECTIVENESS in ION BEAM THERAPY TECHNICAL REPORTS SERIES No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RELATIVE BIOLOGICAL EFFECTIVENESS in ION BEAM THERAPY TECHNICAL REPORTS SERIES No 10.24 mm technical reportS series no. 46i This report covers all the aspects of the relative biological effectiveness (RBE) of ion beams, including laboratory measurements of RBE and the important variables that influence it, dose related quantities and units, and approaches to the clinical use of the concept of RBE based on experimental findings, theoretical models, and previous clinical experience with fast neutrons and ions. RBE is a simple concept but its clinical Technical Reports SeriEs No. 46i application is complex. Future developments in ion therapy will require a coherent approach to the reporting of therapies and their outcomes, not only for comparison with other ion facilities but also with conventional and newly developing photon irradiation techniques. The report is the result of a joint initiative between the IAEA and the International Commission on Radiation Relative Biological Units and Measurements, and is the only current extensive review of ion RBE. Relative Biological Effectiveness in Therapy Ion Beam Effectiveness in Ion Beam Therapy Jointly sponsored by the IAEA and ICRU INTERNATIONAL ATOMIC ENERGY AGENCY VIENNA ISBN 978–92–0–107807–0 ISSN 0074–1914 07-32641_D461_CovI-IV.indd 1 2008-04-01 10:47:19 RELATIVE BIOLOGICAL EFFECTIVENESS IN ION BEAM THERAPY TECHNICAL REPORTS SERIES No. 461 RELATIVE BIOLOGICAL EFFECTIVENESS IN ION BEAM THERAPY JOINTLY SPONSORED BY THE INTERNATIONAL ATOMIC ENERGY AGENCY AND THE INTERNATIONAL COMMISSION ON RADIATION UNITS AND MEASUREMENTS INTERNATIONAL ATOMIC ENERGY AGENCY VIENNA, 2008 COPYRIGHT NOTICE All IAEA scientific and technical publications are protected by the terms of the Universal Copyright Convention as adopted in 1952 (Berne) and as revised in 1972 (Paris). The copyright has since been extended by the World Intellectual Property Organization (Geneva) to include electronic and virtual intellectual property. Permission to use whole or parts of texts contained in IAEA publications in printed or electronic form must be obtained and is usually subject to royalty agreements. Proposals for non-commercial reproductions and translations are welcomed and considered on a case-by-case basis. Enquiries should be addressed to the IAEA Publishing Section at: Sales and Promotion, Publishing Section International Atomic Energy Agency Wagramer Strasse 5 P. O. B o x 1 0 0 1400 Vienna, Austria fax: +43 1 2600 29302 tel.: +43 1 2600 22417 email: [email protected] http://www.iaea.org/books © IAEA, 2008 Printed by the IAEA in Austria February 2008 STI/DOC/010/461 IAEA Library Cataloguing in Publication Data Relative biological effectiveness in ion beam therapy / jointly sponsored by the International Atomic Energy Agency and the International Commission on Radiation Units and Measurements. — Vienna : International Atomic Energy Agency, 2008. p. ; 24 cm. — (Technical reports series, ISSN 0074–1914 ; no. 461) STI/DOC/010/461 ISBN 978–92–0107807–0 Includes bibliographical references. 1. Ion bombardment — Therapeutic use. I. International Atomic Energy Agency. II. Series : Technical reports series (International Atomic Energy Agency) ; 461. IAEAL 08–00503 FOREWORD The use of ion beams for radiation therapy was first explored at the University of California’s Lawrence Berkeley National Laboratory, in the United States of America, and is currently undergoing investigation at institutions in both Japan and Germany with other facilities which are under development or planned. With respect to a role in radiation therapy, ion beams have two important features arising both from the physical aspects of their dose distribution in the patient and from potentially advantageous biological phenomena resulting from their high rate of energy deposition (high linear energy transfer (LET)) over a portion of the particle track which can often be located in the tumour volume. Probably the most important of these biological phenomena is a markedly increased efficiency of cell killing. The concept of relative biological effectiveness (RBE) has been introduced to account for this increased efficiency. RBE is defined as the ratio of a dose of photons to a dose of any other particle to produce the same biological effect. RBE is a simple concept but its clinical application is complex because it is a function of particle type, energy, dose, dose per fraction, fraction number, cell or tissue type, and varies between early and late reactions following therapy. Future developments in ion therapy will require a coherent approach to the reporting of therapies and their outcomes for comparison not only with other ion facilities but also with conventional and newly developing photon irradiation techniques. The International Commission on Radiation Units and Measurements (ICRU) has been involved in the production of a series of reports aimed at rationalizing the reporting of various forms of radiation therapy. Collaboration between the IAEA and the ICRU was initiated for proton therapy. The present publication reflects a continuation of the collaboration between the IAEA and the ICRU, and represents a beginning step in an attempt to standardize the reporting of ion beam radiotherapy using concepts previously developed by the ICRU for reporting other therapies but with special emphasis on the use and reporting of weighting factors related to RBE. Such standardization will facilitate the comparison of therapeutic results obtained with ions not only between centres using this approach but also with centres using other modern forms of radiation therapy, such as proton and intensity modulated radiation therapy with photon beams. A Technical Meeting on Relative Biological Effectiveness in Ion Beam Therapy, jointly sponsored by the IAEA and the ICRU, was held in Vienna, in June 2004. The meeting dealt primarily with the review of experimental measurements of RBE and approaches to the clinical use of the concept of RBE based on experimental findings, theoretical models and previous clinical experience with fast neutrons and ions. Four of the papers presented at this meeting appear as Annexes I–IV in this publication. They were selected as examples related to methods used in different research centres. This publication was prepared by an editorial group comprising E. Blakely of the Lawrence Berkeley National Laboratory, J. Hendry of the IAEA, and P. DeLuca, R. Gahbauer, B. Michael, A. Wambersie and G. Whitmore of the ICRU. The group was chaired by G. Whitmore. The IAEA officer responsible for this publication was J. Hendry of the Division of Human Health. EDITORIAL NOTE Although great care has been taken to maintain the accuracy of information contained in this publication, neither the IAEA nor its Member States assume any responsibility for consequences which may arise from its use. The use of particular designations of countries or territories does not imply any judgement by the publisher, the IAEA, as to the legal status of such countries or territories, of their authorities and institutions or of the delimitation of their boundaries. The mention of names of specific companies or products (whether or not indicated as registered) does not imply any intention to infringe proprietary rights, nor should it be construed as an endorsement or recommendation on the part of the IAEA. CONTENTS 1. RELATIVE BIOLOGICAL EFFECTIVENESS IN ION BEAM THERAPY. 1 1.1. Introduction . 1 1.1.1. Role of radiation therapy in the treatment of cancer . 1 1.1.2. Present situation and future trends . 2 1.1.3. Rationale for ion therapy . 3 2. BIOLOGICAL WEIGHTING OF ABSORBED DOSE: THE SPECIFIC ISSUE OF RBE IN ION BEAM THERAPY . 8 2.1. Absorbed dose . 8 2.2. Need for weighting factors . 9 2.3. Reference irradiation conditions . 10 2.3.1. Radiation quality . 10 2.3.2. Reference fractionation scheme . 10 2.4. Fractionated external photon therapy . 11 2.4.1. Weighting factor for differences in dose per fraction . 11 2.4.2. Example . 12 2.5. Brachytherapy and differences in dose rate . 12 2.6. Influence of overall time . 13 2.7. Radiation quality and RBE . 14 2.7.1. The RBE concept . 14 2.7.2. Application of the RBE concept in radiation therapy . 14 2.7.2.1. RBE and dose prescription . 15 2.7.2.2. Selection of the most clinically relevant RBE or weighting factors for ions . 18 2.7.2.3. Selection of Wion based on the linear quadratic model . 19 2.7.2.4. Evaluation of WIsoE from clinical considerations or outcomes . 22 2.7.3. Ion RBE in therapy applications: Summary . 23 3. QUANTITIES AND UNITS . 26 3.1. Absorbed dose, D . 26 3.2. Biological weighting factor, WB . 27 3.2.1. Fractionated photon beam therapy . 27 3.2.2. Brachytherapy . 28 3.2.3. External beam therapy with non-conventional radiation quality . 28 3.3. Biologically weighted absorbed dose, DB . 29 3.4. Recommendations for reporting . 30 3.4.1. Reporting the isoeffective dose weighting factor, WIsoE. 30 3.4.2. General recommendations for reporting radiation therapy . 31 3.4.3. Review of some current practices for weighting and reporting weighted dose and isoeffective dose in centres using particle irradiations . 31 3.4.3.1. Proton beam therapy . 31 3.4.3.2. The Darmstadt–Heidelberg approach in carbon ion therapy . 32 3.4.3.3. The Chiba approach in carbon ion therapy . 32 3.4.3.4. Equivalent dose . 32 3.4.4. ICRU/IAEA recommendations for reporting the isoeffective dose, DIsoE . 33 4. RADIOBIOLOGY OF HIGH LET RADIATION: NEUTRONS AND IONS . 36 4.1. Radiobiological rationale for the use of high LET radiation . 36 4.1.1. Increased RBE . 36 4.1.2. Reduction in the oxygen enhancement ratio with increasing LET . 39 4.1.3. Reduction of the variation in radiosensitivity related to the position of the cell in the mitotic cycle . 40 4.1.4. Reduced repair with high LET radiation . 41 4.1.5. Effect of tumour differentiation and growth rate . 43 4.2. Patient selection for high LET radiotherapy . 45 4.3.
Load more

Recommended publications
  • Proposed Method for Measuring the LET of Radiotherapeutic Particle Beams Stephen D
    University of New Mexico UNM Digital Repository Physics & Astronomy ETDs Electronic Theses and Dissertations Fall 11-10-2017 Proposed Method for Measuring the LET of Radiotherapeutic Particle Beams Stephen D. Bello University of New Mexico - Main Campus Follow this and additional works at: https://digitalrepository.unm.edu/phyc_etds Part of the Astrophysics and Astronomy Commons, Health and Medical Physics Commons, Other Medical Sciences Commons, and the Other Physics Commons Recommended Citation Bello, Stephen D.. "Proposed Method for Measuring the LET of Radiotherapeutic Particle Beams." (2017). https://digitalrepository.unm.edu/phyc_etds/167 This Dissertation is brought to you for free and open access by the Electronic Theses and Dissertations at UNM Digital Repository. It has been accepted for inclusion in Physics & Astronomy ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact [email protected]. Dedication To my father, who started my interest in physics, and my mother, who encouraged me to expand my mind. iii Acknowledgments I’d like to thank my advisor, Dr. Michael Holzscheiter, for his endless support, as well as putting up with my relentless grammatical errors concerning the focus of our research. And Dr. Shuang Luan for his feedback and criticism. iv Proposed Method for Measuring the LET of Radiotherapeutic Particle Beams by Stephen Donald Bello B.S., Physics & Astronomy, Ohio State University, 2012 M.S., Physics, University of New Mexico, 2017 Ph.D, Physics, University of New Mexico, 2017 Abstract The Bragg peak geometry of the depth dose distributions for hadrons allows for precise and e↵ective dose delivery to tumors while sparing neighboring healthy tis- sue.
    [Show full text]
  • 30. Radioactivity and Radiation Protection 1 30
    30. Radioactivity and radiation protection 1 30. RADIOACTIVITY AND RADIATION PROTECTION Revised August 2011 by S. Roesler and M. Silari (CERN). 30.1. Definitions [1,2] 30.1.1. Physical quantities : • Fluence, Φ (unit: 1/m2): The fluence is the quotient of dN by da, where dN is the number of particles incident upon a small sphere of cross-sectional area da Φ = dN/da . (30.1) In dosimetric calculations, fluence is frequently expressed in terms of the lengths of the particle trajectories. It can be shown that the fluence, Φ, is given by Φ = dl/dV, where dl is the sum of the particle trajectory lengths in the volume dV . • Absorbed dose, D (unit: gray, 1 Gy=1 J/kg=100 rad): The absorbed dose is the energy imparted by ionizing radiation in a volume element of a specified material divided by the mass of this volume element. • Kerma, K (unit: gray): Kerma is the sum of the initial kinetic energies of all charged particles liberated by indirectly ionizing radiation in a volume element of the specified material divided by the mass of this volume element. • Linear energy transfer, L or LET (unit: J/m, often given in keV/µm): The linear energy transfer is the mean energy, dE, lost by a charged particle owing to collisions with electrons in traversing a distance dl in matter. Low-LET radiation: x rays and gamma rays (accompanied by charged particles due to interactions with the surrounding medium) or light charged particles such as electrons that produce sparse ionizing events far apart at a molecular scale (L < 10 keV/µm).
    [Show full text]
  • Alpha Emitting Radionuclides and Radiopharmaceuticals for Therapy"
    Report Technical Meeting on "Alpha emitting radionuclides and radiopharmaceuticals for therapy" June, 24−28, 2013 IAEA Headquarters, Vienna, Austria 1 BACKGROUND An alpha (α)-particle is a ionised 4He nucleus with a +2 electric charge and, therefore, it is relatively heavier than other subatomic particles emitted from decaying radionuclides such as electrons, neutrons, and protons. Because of this physical properties, α-particles are more effective ionization agents with linear energy transfer (LET) of the order of magnitude of 100 keV/µm, and are highly efficient in depositing energy over a short range in tissue (50–100 µm). Actually, a α-particle deposits 1500 times more energy per unit path length than a β- particle. The high mean energy deposition in tissues gives α-radiation exquisite cytotoxicity, which commonly manifests itself within the range of cell’s dimensions. This high LET may allow for an accurately controlled therapeutic modality that can be targeted to selected malignant cells with negligible burden to normal tissues. The short path length renders α-emitters suitable for treatment of minimal disease such as micro metastases or residual tumour after surgical resection of a primary lesion, hematologic cancers, infections, and compartmental cancers. A highly desirable goal in cancer therapy is the ability to target malignant cells while sparing normal cells. If significant differential targeting is achieved by a radiolabelled vector specifically designed to hold onto cancer cells, then a toxic payload on the vector will deliver a lethal dose preferentially to those cells expressing higher concentrations of the target molecule. This could be achieved by using highly cytotoxic α-particle radiation carried to specific sites of cancer cells by appropriate vectors.
    [Show full text]
  • August 31, 1963 NATURE 923
    No. 4896 August 31, 1963 NATURE 923 RADIOBIOLOGY missed, as Berry, Oliver and Porter seem to suggest, though their imputation that cost is our sole consideration A Fast-neutron Source for Radiotherapy is, of course, incorrect. IN a recent note, Lomer and Greene1 have recommended It is perhaps worth enlarging a little on the importance the development of a 14-MeV fast-neutron source for of compactness. In radiotherapy accurate direction of the radiotherapy. We feel that there are disadvantages to beam at the tumour is a primary consideration, and this is this approach. The relative biological effectiveness of best achieved by using a flexibly mounted radiation source fast neutrons is related to their linear energy transfer, so that the beam may be moved with respect to a com­ which in turn varies inversely with the energy of the fortably placed patient, rather than the patient 'lined up' neutron•,•. It has been shown that cell-killing by 1-2- to the machine: compactness is thus important because it facilitates MeV neutrons (linear energy transfer, 50-60 keV/µ) is accurate treatment. relatively independent of oxygen•. As the energy of the We are, of course, well aware that designing a neutron neutrons is increased, the effect becomes more oxygen­ collimator is a problem, and the solution of this problem dependent•-30-MeV neutrons would have a linear energy is naturally an important part of our development pro­ gra,mme. transfer similar to 250-kV X-rays, and hence a similar oxygen-dependence. Tf one is to expect an improvement Furthermore, even if 14-MeV neutrons prove to have no in the results of radiotherapy due to the relative oxygen­ biological advantage over megavoltage X-rays, the D-T source independence of the effect of fast neutrons, then one must may still be competitive with high-energy X-ray units, attempt to use those neutrons the effects of which are in so far as there are reasonable grounds for believing relatively oxygen-independent; this cannot be claimed that they will produce similar dose distributions inside a patient.
    [Show full text]
  • Alpha Emitters for Radiotherapy: Basic Radiochemistry to Clinical Studies Part 1
    Journal of Nuclear Medicine, published on March 15, 2018 as doi:10.2967/jnumed.116.186338 Alpha Emitters for Radiotherapy: Basic Radiochemistry to Clinical Studies _ Part 1 Running title: Alpha Emitters for Radiotherapy Sophie Poty1, Lynn C. Francesconi2,3, Michael R. McDevitt1,4, Michael J. Morris,5 Jason S. Lewis1,6 1Department of Radiology and the Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 2Department of Chemistry, Hunter College, New York, NY, USA 3The Graduate Center of the City University of New York, New York, NY, USA 4Departments of Radiology, Weill Cornell Medical College, New York, NY, USA 5Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA 6Departments of Radiology and Pharmacology, Weill Cornell Medical College, New York, NY, USA Correspondence: Jason S. Lewis, PhD, 1275 York Avenue, New York, NY 10065, USA. Phone: 646-888-3038, FAX: 646-422-0408, Email: [email protected] First author: Sophie Poty, PhD, 1275 York Avenue, New York, NY 10065, USA. Phone: 646- 888-3080, FAX: 646-422-0408, Email: [email protected] Word count: 5317 Disclaimer: The authors have nothing to disclose. Financial support: The authors gratefully acknowledge the Radiochemistry and Molecular Imaging Probe core, which was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748. We gratefully acknowledge Mr. William H. and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research and The Center for Experimental Therapeutics of Memorial Sloan Kettering Cancer Center (JSL) and the fellowship from the François Wallace Monahan Fellowship from the JLM Benevolent Fund (SP).
    [Show full text]
  • The Biological Effects of Space Radiation During Long Stays in Space
    Biological Sciences in Space, Vol.18 No.4 (2004):Ohnishi, 201-205 K. and Ohnishi, T. © 2004 Jpn. Soc. Biol. Sci. Space The Biological Effects of Space Radiation during Long Stays in Space Ken Ohnishi and Takeo Ohnishi Department of Biology, Nara Medical University School of Medicine,Shijo-cho 840, Kashihara, Nara 634-8521, Japan. Abstract Many space experiments are scheduled for the International Space Station (ISS). Completion of the ISS will soon become a reality. Astronauts will be exposed to low-level background components from space radiation including heavy ions and other high-linear energy transfer (LET) radiation. For long-term stay in space, we have to protect human health from space radiation. At the same time, we should recognize the maximum permissible doses of space radiation. In recent years, physical monitoring of space radiation has detected about 1 mSv per day. This value is almost 150 times higher than that on the surface of the Earth. However, the direct effects of space radiation on human health are currently unknown. Therefore, it is important to measure biological dosimetry to calculate relative biological effectiveness (RBE) for human health during long-term flight. The RBE is possibly modified by microgravity. In order to understand the exact RBE and any interaction with microgravity, the ISS centrifugation system will be a critical tool, and it is hoped that this system will be in operation as soon as possible. Key words; space, space radiation, biological effect, high-LET, ISS Characteristics of space and the composition of space radiation the radiation being composed of α-particles and heavy For several years, human beings have been particles.
    [Show full text]
  • Alpha-Particles for Targeted Therapy Advanced Drug Delivery Reviews
    Advanced Drug Delivery Reviews 60 (2008) 1402–1406 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Alpha-particles for targeted therapy☆ George Sgouros Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore MD USA ARTICLE INFO ABSTRACT Article history: Alpha-particles are helium nuclei that deposit DNA damaging energy along their track that is 100 to 1000 Received 18 October 2007 times greater than that of conventionally used beta-particle emitting radionuclides for targeted therapy; the Accepted 16 April 2008 damage caused by alpha-particles is predominately double-stranded DNA breaks severe enough so as to be Available online 23 April 2008 almost completely irreparable. This means that a small number of tracks through a cell nucleus can sterilize a cell and that, because the damage is largely irreparable, alpha-particle radiation is not susceptible to Keywords: fl Alpha-particle resistance as seen with external radiotherapy (e.g., in hypoxic tissue). The ability of a single track to in uence Targeted therapy biological outcome and the stochastic nature of alpha-particle decay require statistical or microdosimetric Dosimetry techniques to properly reflect likely biological outcome when the biologically relevant target is small or when a low number of radionuclide decays have occurred. In therapeutic implementations, microdosimetry is typically not required and the average absorbed dose over a target volume is typically calculated. Animal and cell culture studies have shown that, per unit absorbed dose, the acute biological effects of alpha- particles are 3 to 7 times greater than the damage caused by external beam or beta-particle radiation.
    [Show full text]
  • Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications
    pharmaceutics Review Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications Bryce J. B. Nelson 1, Jan D. Andersson 1,2 and Frank Wuest 1,* 1 Department of Oncology, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada; [email protected] (B.J.B.N.); [email protected] (J.D.A.) 2 Edmonton Radiopharmaceutical Center, Alberta Health Services, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada * Correspondence: [email protected]; Tel.: +1-780-391-7666; Fax: +1-780-432-8483 Abstract: This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α-particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and radiochemistry of common α-emitters, including 225Ac, 213Bi, 224Ra, 212Pb, 227Th, 223Ra, 211At, and 149Tb; the production techniques and proper handling of α-emitters in a radiopharmacy; recent preclinical developments; ongoing and completed clinical trials; and an outlook on the future of TAT. Keywords: targeted alpha therapy; alpha particle therapy; targeted radionuclide therapy; theranos- tics; actinium-225; bismuth-213; astatine-211; radium-223; thorium-227; terbium-149 1. Introduction Radionuclide therapy has been employed frequently in the past several decades Citation: Nelson, B.J.B.; Andersson, for disease control, curative therapy, and pain management applications [1]. Targeted J.D.; Wuest, F. Targeted Alpha radionuclide therapy (TRT) is advantageous as it delivers a highly concentrated dose to a Therapy: Progress in Radionuclide tumor site—either directly to the tumor cells or to its microenvironment—while sparing Production, Radiochemistry, and the healthy surrounding tissues.
    [Show full text]
  • And Relative Biological Efficiency (RBE) Linear Energy Transfer (LET)
    L3 Linear Energy Transfer (LET) and Relative Biological Efficiency (RBE) Linear energy transfer (LET) It describes how much energy an ionizing particle transfers to the material (transverse per unit distance). Or the amount of energy a radiation deposits per unit of path length (i.e., kilo electron volts/micron - Kev/µm).It describes the action of radiation into matter. LET is a positive quantity, depends on the nature of the radiation as well as on the material traversed. LET increases with the square of the charge on the incident particle. When ionizing radiation interacts within cells, it deposits ionizing energy in the cell .The higher the charge of the particle and the lower the velocity, the greater likelihood to produce ionization. Linear energy transfer (LET) A measure of the rate at which energy is transferred from ionizing radiation to soft tissue Mass, charge and velocity of a particle all affect the rate at which ionization occurs and is related to range. (Heavy, highly charged particles (e.g., α-particle) lose energy rapidly with distance and do not penetrate deeply. In general, radiation with a long range (e.g., x-/γ-rays, high energy ß- particles) usually has a low LET, While large particulate radiations with short range (e.g., α-particles, neutrons, protons) have a high LET. • LET is number of ionizations which radiation causes per unit distance as it traverses the tissue • Medical x-rays and gamma rays are low LET. LET of diagnostic x-rays is 3.0 • Alpha particles are high LET - about 100.0 • LET varies with type of radiation • LET is potential ionization Relative Biologic Effectiveness, RBE It is the ratio of biological effectiveness of one type of ionizing radiation relative to another, given the same amount of absorbed energy.
    [Show full text]
  • Arxiv:1710.07311V4 [Physics.Med-Ph] 17 Feb 2018 80 Years of Solar Measurements
    Limitations in Predicting the Space Radiation Health Risk for Exploration Astronauts Jeffery C. Chancellor,1 Rebecca S. Blue,2 Keith A. Cengel,3 Serena M. Auñón-Chancellor,4, 5 Kathleen H. Rubins,5 Helmut G. Katzgraber,1, 6, 7 and Ann R. Kennedy3 1Department of Physics and Astronomy, Texas A&M University, College Station, TX 77843-4242, USA 2Aerospace Medicine and Vestibular Research Laboratory, The Mayo Clinic Arizona, Scottsdale, AZ 85054, USA 3Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA 4University of Texas Medical Branch, Galveston, TX 77555, USA 5National Aeronautics and Space Administration (NASA), Johnson Space Center, Houston, TX 77058, USA 61QB Information Technologies (1QBit), Vancouver, British Columbia, V6B 4W4, Canada 7Santa Fe Institute, 1399 Hyde Park Road, Santa Fe, NM 87501, USA Keywords: space radiation; radiobiology; aerospace medicine; interplanetary; animal model; clinical; mono- energetic; solar particle event; galactic cosmic ray. Running Title: Predicting Space Radiation Risk Despite years of research, understanding of the released Report No. 98: Guidance On Radiation Re- space radiation environment and the risk it poses to ceived in Space Activities.1 In this report, authors rec- long-duration astronauts remains limited. There is ommended that NASA astronauts be limited to career a disparity between research results and observed lifetime radiation exposures that would induce no more empirical effects seen in human astronaut crews, than a 3% Risk of Exposure-Induced Death (REID). likely due to the numerous factors that limit terres- This was re-emphasized in the 2015 NCRP Commen- trial simulation of the complex space environment tary No.
    [Show full text]
  • Particle Radiation in Microelectronics
    DEPARTMENT OF PHYSICS UNIVERSITY OF JYVÄSKYLÄ RESEARCH REPORT No. 5/2012 Particle radiation in microelectronics BY ARTO JAVANAINEN Academic Dissertation for the Degree of Doctor of Philosophy to be presented, by permission of the Faculty of Mathematics and Science of the University of Jyväskylä, for public examination in Auditorium FYS 1 of the University of Jyväskylä on June 20, 2012 at 12 o’clock noon Jyväskylä, Finland June 2012 To our beloved daughters Iida and Edla “Mielikuvitus on tietoa tärkeämpää” “Imagination is more important than knowledge” — Albert Einstein Preface The work reported in this thesis has been carried out over the years 2005–2012 at the Accelerator Laboratory of the University of Jyväskylä. It has been a great pleasure to work in the RADEF group all these years. Most of all, I want to thank my supervisor Dr. Ari Virtanen for his endless patience and all the fruitful conversations we have had about physics and beyond. Very special thanks go to Mr. Reno Harboe-Sørensen from the European Space Research and Technology Centre of the European Space Agency. Reno’s extraordinary experience in the field of radiation effects and his invaluable guidance have been the main driving forces for this work and the whole existence of RADEF facility. Dr. Heikki Kettunen and Mr. Mikko Rossi deserve my thanks for all the help they have offered me over the years in various experiments. Also I have to thank Dr. Iiro Riihimäki, whose impact on this work cannot be ignored. I want to thank Dr. Tomek Malkiewicz, Dr. Jarek Perkowski and Mr.
    [Show full text]
  • Linear Energy Transfer
    Linear Energy Transfer (LET) dependence of BANG® polymer gel dosimeters in proton beams Whitney Bivens*1, Geoffrey Ibbott*1, Marek Maryanski*2, Malcolm Heard*1, David Followill*1, Ronald Zhu*1, (1) UT MD Anderson Cancer Center, Houston, TX, (2) MGS Research, Inc., Guilford, CT Radiological Physics Center, The University of Texas M. D. Anderson Cancer Center 7515 S. Main St. Suite 300, Houston, TX 77030 4Gy Introduction Results In clinical radiotherapy, polymer gel dosimeters can BANG®3 polymer gel dosimeters had a linear dose provide precise and high-resolution verification of complex three- response for both protons and photons. A transverse image of an dimensional dose distributions. Polymer gel dosimetry is based on 2Gy optical CT scan of the BANG®3 used to assess the dose response the radiation-induced polymerization of acrylic monomers infused in of the gel is displayed in Fig. 2. As well, the linear relationship of a gelatin matrix.1 This change in gel structure can be observed and the optical CT attenuation to dose of BANG®3 gels for both proton quantified using Optical Computed Tomography (OCT). and photon beams can be seen in Fig. 3 and Fig. 4. Proton therapy is becoming increasingly useful as an ® Relative dose was evaluated for the depth dose external beam radiotherapy modality because of its characteristic Figure 1. Schematic of the bottom view of the irradiated gel. Figure 2. Optical CT scan of gel used for the BANG 3 proton dose response distributions using the dose response curve obtained in the proton curve. The lightest quadrant on the bottom right represents the highest dose ® -3 dose distribution.
    [Show full text]